Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | FBXO5 | CTRPv2 | pan-cancer | AAC | 0.2 | 1e-08 |
mRNA | HNRNPH1 | CTRPv2 | pan-cancer | AAC | 0.2 | 1e-08 |
mRNA | MPHOSPH9 | CTRPv2 | pan-cancer | AAC | 0.2 | 1e-08 |
mRNA | MBD3 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-08 |
mRNA | ZNF407 | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-08 |
mRNA | SRRT | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-08 |
mRNA | BRD3 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-08 |
mRNA | REXO2 | CTRPv2 | pan-cancer | AAC | -0.18 | 2e-08 |
mRNA | CBX5 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-08 |
mRNA | PSIP1 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-08 |